Strategy+ is advising one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on a joint venture with GlaxoSmithKline plc (NYSE:GSK) to create a premier global consumer healthcare company with robust iconic brands. Under the transaction, Pfizer will contribute its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business. The agreement was announced December 18, 2018. The Joint Venture was valued at $16 Billion.
Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
